Biotech

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update

Stock market news /

Key Takeaways Invivyd, Inc. (**$IVVD**) reported **Q4 2025 revenue** of **$25.3 million**, exceeding analyst consensus estimates of $23.5 million, per the Invivyd Q4 2025 Earnings Call Presentation. The company posted an adjusted **net loss** of **-$0.15 per share** for Q4, outperforming analyst expectations of a -$0.20 loss, according to the same presentation. Positive interim data […]

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update Read More »

MiMedx Group Reveals Robust Q4 2025 Results Amidst Strategic Growth Initiatives

Stock market news /

$MDXG Reports Strong Q4 2025 Performance, Exceeding Revenue Forecasts Key Takeaways MiMedx Group, Inc. (MDXG) reported Q4 2025 revenue of $110.3 million, marking a significant 15.2% increase year-over-year, surpassing analyst consensus, per Q4 2025 Earnings Call Transcript. Net income for the quarter reached $12.5 million, translating to $0.09 per diluted share, demonstrating improved profitability and

MiMedx Group Reveals Robust Q4 2025 Results Amidst Strategic Growth Initiatives Read More »

$VRTX Earnings Report Scheduled for February 12

Stock market news /

Vertex Pharmaceuticals ($VRTX), the biotechnology giant renowned for its transformative cystic fibrosis (CF) therapies, is set to report its latest quarterly earnings on February 12. This highly anticipated announcement will offer critical insights into the company’s financial health, the sustained performance of its market-leading CF drugs, and the progress of its expansive pipeline targeting severe

$VRTX Earnings Report Scheduled for February 12 Read More »